CA-ARROW-ELECTRONICS
14.3.2023 09:02:14 CET | Business Wire | Press release
Arrow Electronics, Inc. and Qualcomm Technologies International, Ltd. have expanded their strategic collaboration. The establishment of Edge Labs — an Arrow Center of Excellence (CoE) — will help customers accelerate the development of connected intelligent edge devices based on solutions from Qualcomm Technologies.
Edge and AI solution development is becoming increasingly challenging to customers due to several factors such as lack of prior experience, limited access to high-performance edge and AI chipsets, supply chain complexity and fledgling ecosystem. Edge Labs aims to help innovators navigate these challenges while increasing the adoption of Edge AI using solutions from Qualcomm Technologies across security, safety, healthcare, robotics, cameras, displays, optical inspection and other IoT applications.
Edge Labs will have a dedicated solution architect and engineering team to develop application-specific solutions, including training sales and field application engineers specifically on Qualcomm Technologies’ products. It will also offer design services to enable lower risk and faster time to market for customers through eInfochips, an Arrow company.
“We are excited to expand our collaboration with Qualcomm Technologies and establish Edge Labs, an Arrow center of excellence,” said Kirk Schell, president of Arrow’s global components business. “Combining Arrow’s strength in engineering and supply chain with Qualcomm Technologies’ innovative products will help customers accelerate their design and speed to market in robotic, edge appliance and machine vision applications.”
Customers can rely on Edge Labs to deliver innovative and leading edge products, accelerate and de-risk design cycles, leverage the Aikri™ portfolio of SOMs and development kits, and get access to a world-class support team enabling them to plan and manage their product roadmap and lifecycles.
"Edge AI is the next big engineering frontier and we’re thrilled to expand our strategic collaboration with Arrow Electronics to strengthen the development and proliferation of IoT technologies and serve a more diverse and global customer base,” said Dev Singh, vice president, business development, Qualcomm Technologies, Inc. “Edge Labs CoE customers will have the ability to unlock new and unique edge AI use cases thanks to Qualcomm Technologies’ leading edge platforms and unified SW stack."
The first development kit from eInfochips as part of the Edge Labs initiative, “Aikri 42x”, based on Qualcomm QRB4210 SoC, has just launched and is being demonstrated at Embedded World conference, March 14-16, in Messe, Nuremberg, Germany.
To learn more and to collaborate with Edge Labs, visit Embedded World (Hall 3A.135), www.arrow.com/edgelabs and www.einfochips.com/edgelabs or edgelabs@arrow.com or edgelabs@einfochips.com.
About Arrow Electronics
Arrow Electronics guides innovation forward for over 210,000 leading technology manufacturers and service providers. With 2022 sales of $37 billion, Arrow develops technology solutions that improve business and daily life. Learn more at fiveyearsout.com.
About eInfochips
eInfochips, an Arrow Electronics company, is a leading provider of digital transformation and product engineering services. With 500-plus products developed and 40 million deployments in 140 countries, eInfochips continues to fuel technological innovations in multiple verticals.
eInfochips accelerates time to market for its customers with its expertise in the areas of cloud, IoT, AI/ML, digital twins, hyper automation, and cybersecurity.
About Qualcomm
Qualcomm is enabling a world where everyone and everything can be intelligently connected. Our one technology roadmap allows us to efficiently scale the technologies that launched the mobile revolution — including advanced connectivity, high-performance, low-power compute, on-device intelligence and more — to the next generation of connected smart devices across industries. Innovations from Qualcomm and our family of Snapdragon platforms will help enable cloud-edge convergence, transform industries, accelerate the digital economy, and revolutionize how we experience the world, for the greater good.
Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of our engineering, research and development functions, and substantially all of our products and services businesses, including our QCT semiconductor business. Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005495/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom